extensively used for the treatment of chronic renal failure for more than 20 years, the biocompatibility of
Introduction

Subiects and methods
centres as follows; Cardiff Royal Infirmary, UK (n=13), ory on plasma or whole blood samples as appropriate: Na+, K+, Cl−, lactate, bicarbonate, pCO 2 total CO 2 , pH, total Hope Hospital. Salford, UK (n=15), Guy's Hospital, London, UK (n=14), Manchester Royal Infirmary. UK calcium, ionized calcium, magnesium, phosphate, urea, creatinine, glucose, total protein, albumin, alkaline phosphatase, (n=9), and Brescia, Italy (n=8). Each patient gave written informed consent, and approval for the study was given by SGOT (aspartate transaminase), SGPT (alanine transaminase), and osmolality. In addition, plasma bicarbonate levels the individual ethics committee for each centre. The study conforms to the Declaration of Helsinki and the Good were assessed at the end of the first week.
A lactate and bicarbonate balance was determined in one Clinical Practice guidelines for clinical trials of the European Union.
centre (Brescia), in 2 or 3 patients from each study group, and was performed during two consecutive exchanges: during a 4-h 1.36% exchange followed by a 4 h 3.86% exchange (on
Study population
control or experimental solutions). The balance was performed at day 1, after 1 month and during the last week of Adult patients who had been treated by CAPD for at least the 2-month study. The infused volume (2 litres) was recorded 3 months were eligible for the study. Patients were included as well as the drain volume. The patients used 1.36% dialysis if they had; been receiving a dialysis solution containing solution for the overnight solution preceding the lactate and 40 mmol/l lactate with a calcium concentration of bicarbonate balance dwells. 1.25 mmol/l (DianealB PD4, Baxter Healthcare) for at least
The plasma bicarbonate level was the primary measure of 1 month; a residual renal function of ∏5 ml/min; a weekly efficacy and was measured on venous blood, sampled without (renal+peritoneal ) creatinine clearance of Á50 l/1.73 m2 of stasis, using a blood gas analyser. Blood was taken into a body surface area, and a weekly Kt/VÁ1.5. In addition, if heparinized syringe and immediately transported to the local prescribed, sodium bicarbonate was stopped at least 4 days laboratory for analysis. Actual plasma bicarbonate was before the trial commenced. Patients were excluded if they; calculated by the blood gas analyser from pH and pCO 2 had low peritoneal transport (4 h dialysis/plasma ratio creati-according to the Henderson-Hasselbalch formula. ine <0.5); were known to be HIV positive; had had peritonitis within the previous 30 days; suffered from liver disease or diabetes mellitus, or if they added any medication routinely Study products to the dialysis bag. All patients were using four or five 2-litre bags per 24 h and should have had no dry period.
The experimental solutions were presented in two-chambered bags. The top chamber contained dextrose, calcium chloride and magnesium chloride. The bottom chamber contained
Study procedures
sodium bicarbonate and sodium chloride with or without sodium lactate. (Baxter Healthcare, Florence, Italy). By After a 2-week baseline period, patients were randomized breaking a frangible seal between the chambers the solutions to receive one of the three study solutions: DianealB mix automatically. Once mixed, the experimental peritoneal PD4 (control ), 38 mmol/l. bicarbonate, or 25 mmol/l dialysis solutions contained 38 mmol/l bicarbonate, or bicarbonate/15 mmol/l. lactate. All three solutions were 25 mmol/l bicarbonate and 15 mmol/l lactate as well as available with 1.36% and 3.86% glucose. Randomization was 1.36% or 3.86% dextrose. The control peritoneal dialysis done separately for each centre in blocks of three with one solutions contained 40 mmol/l of lactate and 1.36% or 3.86% patient allocated to each treatment in each block. The glucose of dextrose (DianealB PD4, Baxter Healthcare). The comconcentration used was determined by patient need. The position of these fluids is listed in Table 1 . main treatment period was 2 months, but an extension of up The single two chambered bag was connected to a disconto 4 months was offered to all patients. A follow-up was nect set in most cases, although a few patients opted to performed 1 month after each patient completed the study.
continue using a non-disconnect system. When using the The prescription of oral calcium carbonate was kept disconnect system, the drain and fill bags as well as the Y-set unchanged during the study unless there was a specific were disconnected and disposed of after each exchange. medical requirement for a change. Also, unless clinically required, neither oral nor intraperitoneal sodium bicarbonate istry tests pre-study, on day 1, weeks 4 and 8, at the end of the extension period, and 1 month after the end of the study.
The following parameters were analysed by the local laborat-aDianealB PD4 (Baxter Healthcare Corporation).
Statistical analyses the extension study. Data on their adverse events only is included in this manuscript. Over this exposure The results were analysed using repeated measures analysis period, (main study plus extension) there were no of variance (ANOVA) for the plasma bicarbonate levels. safety features of concern.
The least-squares means test was used to determine which treatment group was different from the others. Comparisons
Efficacy analysis
between groups were made using t tests and uncorrected Chi-square tests, All statistical tests were two-tailed. For Thirteen patients were excluded from the evaluable repeated measures analysis, the 0.05 level was used for patient population in the efficacy analyses: eight statistical significance.
patients who experienced peritonitis during the treatment period, three patients who were dry overnight, and two patients who were transplanted before the Results end of the 2-month treatment period. Thus 46 subjects, 16 control, 13 bicarbonate and 17 bicarbonate/lactate, Demographics completed the full 8 weeks without any confounding The baseline demographics of the 59 patients enrolled factor and were considered eligible for efficacy evaluin the study are shown in Table 2 . The accumulated ations. In addition individual values were excluded if number of months of therapy in the three groups patients had changes in their prescription of calcium-(excluding baseline and follow up) were 53.9 (control ), containing phosphate binders or if they had other 53.1 (bicarbonate) and 56.1 (bicarbonate/lactate). A alkali sources during this study. This affected the data total of 18 patients (six in each group) continued into at certain time-points for a further five patients. An analysis of variance was therefore done on all patients on an intent-to-treat (ITT ) basis as well as on those second model which adjusted for baseline plasma bicar-Bicarbonate-lactate balance bonate and study centre (ITT P=0.009, evaluable Two to three patients in each group were assessed for group P=0.0083). This shows that the difference buffer uptake from the PD solution. The data are between the groups with regard to the rise in bicarbon-presented in Table 4 . Compared with the control lactate ate levels at week 1, noted above, remains significant group, the bicarbonate/lactate group had, as expected, when all baseline differences between the groups are a lower uptake of lactate, whereas the bicarbonate taken into account. Also, using the least-squares means uptake was highest in the bicarbonate group. The method showed that it was the bicarbonate/lactate buffer uptake was influenced considerably by group which was different from the other two treatment ultrafiltration. groups. Bicarbonate values were also analysed as a function of patient body weight. No clear differences between the three solutions were found.
Renal-function evaluation Biochemistry
There were no significant changes in the residual renal function, weekly Kt/V and normalized renal and periAt most visits, all patients were reported to have toneal creatinine clearances over the study period in several blood biochemistry values that were outside any of the study groups. There were no differences the hospital normal ranges. None of these out-of-range between the groups with regard to change from baseline values were judged to be unexpected. There were as for any of these parameters. many out-of-range values at the baseline and followup visits as at the visits that took place during the treatment period. During the course of the study, eight patients had plasma bicarbonate values >30 mmol/l Solution impact on the peritoneal transport (four in the control group, one in the bicarbonate characteristics group, three in the bicarbonate/lactate group). The alkalosis was regarded as mild and judged to be This was assessed by the peritoneal equilibration test (PET ) derived permeability data using dialysate/ clinically insignificant in all eight patients. One patient in the bicarbonate/lactate group had a plasma bicar-plasma (D/P) ratios. The changes in D/P for urea and creatinine were found to be minor and insignificant bonate which started high at baseline and remained high throughout the study. Plasma lactate levels over the study period for all study groups. There was also no change with regard to ultrafiltration. remained unchanged throughout the study. Adverse events solution, and 1/19 for the bicarbonate/lactate solution.
The episodes of abdominal pain were all in association The most commonly reported adverse events are shown with peritonitis. in Table 5 . None of the adverse events reported were regarded as attributable to the test fluids. None of the between-group differences was clinically significant. In Discussion all there were 17 episodes of peritonitis (not including recurrences) in 13 patients. The overall incidence of Traditionally lactate based fluids have been used for peritonitis in terms of events per month of treatment peritoneal dialysis. These are prepared at low pH to was 1/18. reduce the degradation of glucose during heat sterilisWhen this was broken down by solution, the incidation. The combination of low pH and high lactate ence of peritonitis was 1/22 for the 40 mmol/l lactate concentration adversely affects cell function in particusolution (this includes all pre-study and follow-up lar polymorphonuclear neutophils, macrophages [2] [3] [4] [5] periods for all treatment groups plus the treatment and mesothelial cells in vitro [6, 7] . Adjustment of the period for the control group), 1/11 for the bicarbonate pH reduces this toxicity [8] [9] [10] . Studies show that the intraperitoneal pH rises rapidly and the lactate concen- Table 5 . Most frequently reported (>5%) adverse events tration falls [2] . Despite this equilibration, ex vivo studies show that during short dwells, macrophage
function is impaired when exposed to intraperitoneal (n=19) fluid at acid compared to neutral pH [15, 18] The current study shows that both bicarbonateterm. Adverse events classified according to COSTART coding based solutions corrected the acidosis as effectively as dictionary. B/L, bicarbonate/lactate. the standard solution with 40 mmol/l lactate and did not cause clinically significant alkalosis. The numbers each bag prior to inflow [25] , but this is not practical on a mass basis and will also, by touch contamination of patients for whom plasma bicarbonate levels >30 mmol/l were recorded were similar between the during the addition procedure, increase the risk of peritonitis. The current method of making bicarbonate three treatment groups. Furthermore, these high values were seen during the baseline and follow-up periods PD fluid is to use a two-chamber bag system, whereby sodium bicarbonate and dextrose are in separate comas well as during the treatment period.The transient rise in plasma bicarbonate noted in the bicarbonate/ partments. The two compartments are mixed just prior to inflow by opening a frangible seal. This trial confirms lactate group was very small and must be regarded as clinically insignificant: 27.1 mmol/l at week 1 compared that this type of bag is well accepted by patients.
The peritonitis incidence reported in this study was to 25.7 mmol/l at baseline, a difference of less than 1 SD of the measured values. The 38 mmol/l bicarbonate typical for the type of connection system used. As this was a pilot study, the bags were manufactured separfluid does, however, contain 5% less alkali than the other fluids. We elected to assess the long-term effects ately and not as part of an integrated disconnect system. Patients thus used various systems, including of the fluids on small solute transport using 40 mmol/l lactate for the test solution. This was because all non-disconnect and a system which required an extra connection to the bag to be made. We predict that a published results using the PET to date have used this fluid. As noted, no changes were seen in this study. lower incidence of peritonitis will be seen when a fully integrated system is used. The results of the bicarbonate/lactate balance studies confirm the findings of Feriani et al. [21] that the gain
In an experimental study in rabbits [24] and one human investigation [25] , it was claimed that the use by the patient of buffer is related in part to the dialysate concentration of the relevant ion. With the need to of neutral pH fluid was associated with increased ultrafiltration. We (measuring ultrafiltration as part of increase peritoneal fluid removal as residual renal function is lost, the fact that ultrafiltration was found a 4-h PET ) and others [23] have not been able to confirm this during short-term studies. The reason for in both studies to have a negative influence on buffer gain may mean that the concentration of bicarbonate this discrepancy may be due to the fact that Yamamoto et al. [25] neutralized their lactate-containing solution and/or lactate will have to vary depending on the net osmolar effect of the dialysate.
by adding a concentrated bicarbonate solution, thus raising the osmolality by 7 mosm/kg. It should also be There were no solution-related adverse events. The profile of adverse effects seen in these patients is typical noted that in the rabbit study, glycylglycine was present in the bicarbonate solution, but not the lactate solution. of a CAPD population and is consistent with the expected background events. Our findings thus confirm It is possible that a neutral pH fluid might improve peritoneal viability including maintaining ultrafiltraprevious reports showing that bicarbonate-based dialysis solutions are safe and effective in the treatment tion over the long term. To prove this hypothesis would, however, require a trial involving a large of chronic uraemia [22, 23] .
The choice of 38 mmol/l bicarbonate was based on number of patients studied over a much longer period. Such a study, comparing the bicarbonate/lactate mixa preliminary clinical trial that showed that there was inadequate correction of acidosis with a 33 mmol/l ture with the 40-mmol/l lactate solution, is currently in progress and should provide answers to some of the bicarbonate fluid. A concentration of 38 mmol/l is, however, higher than the normal plasma level of remaining questions.
In conclusion, this study showed that either approximately 25 mmol/l. Though the clinical significance of exposing the peritoneal membrane to a the bicarbonate (38 mmol/l ) or bicarbonate/lactate solutions could be utilized efficaciously in patients supranormal concentration of bicarbonate remains unknown, it has, however, been reported that some undergoing peritoneal dialysis. Acid-base status was maintained. Advantages of bicarbonate-buffered periaspects of cell function are better preserved in vitro or ex vivo when using a bicarbonate/lactate mixture than toneal dialysis solutions over standard lactate-based solutions include less cytotoxic effects on peritoneal with a high bicarbonate concentration alone [14, 15] . For these reasons the mixture of 25 mmol/l bicarbonate cells, reduced pain on infusion, a more physiological correction of acidosis, and a theoretical reduced risk and 15 mmol/l lactate was also tested in this clinical study.
of lactic acidosis. Whether the bicarbonate/lactate mixture will prove to be of more benefit to patients is as Despite the absorption of considerable quantities of lactate from the commercial solution, there were no yet uncertain. differences in plasma lactate levels with the three fluids tested in this study. Thus, otherwise healthy CAPD 
